scFv of a human scaffold targeting Nuclear body protein SP140. Antigen coverage aa 688-862 of 867, Bromodomain

To increase the length of the linker between Venus and Noxa proteins

Golden Gate Compatible TALEN Construct for site specific modification of genome, +63 C Terminus, Codon Optimized FokI

3-exon minigene, with SRSF1 motif-rich middle exon, hnRNPA1 motif-rich region in second intron following a neutral spacer, and AG>GG mutation in final 3' splice site

3-exon minigene, with SRSF1 motif-rich middle exon, hnRNPA1 motif-rich region in second intron, both randomly mutated to avoid sequence repeats, and AG>GG mutation in final 3' splice site

Encodes Poliovirus type I Mahoney VP12A optimized for expression in mammalian transcription/translation extracts

To increase the length of the linker between Venus and Noxa-4E proteins

Produces Yersinia pestis N5-carboxyaminoimidazole ribonucleotide mutase with N-terminal TEV protease-cleavable His6 tag (H6tYpPurE1), synthetic gene

Produces Franciscella tularensis N5-carboxyaminoimidazole ribonucleotide mutase with N-terminal TEV protease-cleavable His6 tag (H6tFtPurE1), synthetic gene

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe10_ChR2_mCherry (#213815). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E10. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.